Concepedia

Cynthia A. Gates

CA

24

Publications

1.9K

Citations

18

H-Index

1981

Active since

Affiliations

Vertex Pharmaceuticals (United States)(Current)

University of Wisconsin–Madison

Eli Lilly (United States)

Cynthia A. Gates is an author at Vertex Pharmaceuticals (United States) specializing in medicine, pharmacology, and drug discovery.

Top concepts

Publications per year

1981–2007

24

Publications

24

Preclinical Profile of VX-950, a Potent, Selective, and Orally Bioavailable Inhibitor of Hepatitis C Virus NS3-4A Serine Protease

Robert B. Perni, Susan J. Almquist, Randal A. Byrn et al. · Antimicrobial Agents and Chemotherapy · 2006 · 382 citations · Full text

Simultaneous PCR detection of Haemophilus ducreyi, Treponema pallidum, and herpes simplex virus types 1 and 2 from genital ulcers

Karina A. Orle, Cynthia A. Gates, David H. Martin et al. · Journal of Clinical Microbiology · 1996 · 318 citations · Full text

, , +20

In Vitro Resistance Studies of Hepatitis C Virus Serine Protease Inhibitors, VX-950 and BILN 2061

Chao Lin, Kai Lin, Yu-Ping Luong et al. · Journal of Biological Chemistry · 2004 · 289 citations · Full text

In Vitro Studies of Cross-resistance Mutations against Two Hepatitis C Virus Serine Protease Inhibitors, VX-950 and BILN 2061

Chao Lin, Cynthia A. Gates, B. Govinda Rao et al. · Journal of Biological Chemistry · 2005 · 216 citations · Full text

, , +14

Synthesis of 21,21-Difluoro-3β-hydroxy-20-methylpregna-5,20-diene and 5,16,20-Triene as potential inhibitors of steroid C17(20) lyase

Philip M. Weintraub, Amy K. Holland, Cynthia A. Gates et al. · Bioorganic & Medicinal Chemistry · 2003 · 79 citations

, , +6

Rows per page

1–5 of 24